Frontline Pembrolizumab for PD-L1–Positive Gastric Cancer: Kohei Shitara, MD

Gastric or gastroesophageal junction (G/GEJ) cancer constitutes the third leading cause of cancer death worldwide, and more therapeutic options are needed. In results from the phase 3 KEYNOTE-062 study, published last week in JAMA Oncology, Kohei Shitara, MD, and colleagues reported that in patients with previously untreated G/GEJ cancer with a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater, pembrolizumab, alone or in combination with chemotherapy, was nonin...
Continue reading

PD-L1–Positive Gastric Cancer: Frontline Pembrolizumab Noninferior to Chemotherapy

Data from the phase 3 KEYNOTE-062 trial have revealed that in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer with a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater, first-line pembrolizumab, alone or in combination with chemotherapy, is noninferior but not superior to chemotherapy alone. In patients with a PD-L1 CPS of 10 or greater, pembrolizumab monotherapy showed a possible benefit, but one that cannot be considered definitive o...
Continue reading

Durvalumab Improves Survival in Advanced Lung Cancer

A new study has demonstrated that durvalumab (Imfinzi®, AstraZeneca) improves survival for patients with stage III, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed after chemoradiotherapy. Durvalumab, an intravenously administered immune checkpoint inhibitor, was approved in February by the United States Food and Drug Administration (FDA) as a standard-of-care treatment for this indication. It works by blocking programmed cell death ligand 1 (PD-L1), a protein fo...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.